6533b851fe1ef96bd12a987d

RESEARCH PRODUCT

Epigenetic biomarkers for human sepsis and septic shock: insights from immunosuppression

José Luis García-jiménezCarlos Romá-mateoCarlos Romá-mateoJosé FerreresSandra MuletJesús Beltrán-garcíaNieves CarbonellRebeca Osca-verdegalMaría RodríguezEva García-lópezFederico V. PallardóFederico V. Pallardó

subject

0301 basic medicineCancer ResearchRNA Untranslatedmedicine.medical_treatmentAdaptive ImmunityBiologyBioinformaticsEpigenesis GeneticHistonesSepsis03 medical and health sciences0302 clinical medicineImmune systemSepsismicroRNAGeneticsmedicineHumansEpigeneticsPathologicalImmunosuppression TherapyEpigenetic biomarkersSeptic shockImmunosuppressionDNA Methylationmedicine.diseaseShock SepticImmunity Innate030104 developmental biology030220 oncology & carcinogenesisBiomarkers

description

Sepsis is a life-threatening condition that occurs when the body responds to an infection damaging its own tissues. Sepsis survivors sometimes suffer from immunosuppression increasing the risk of death. To our best knowledge, there is no ‘gold standard’ for defining immunosuppression except for a composite clinical end point. As the immune system is exposed to epigenetic changes during and after sepsis, research that focuses on identifying new biomarkers to detect septic patients with immunoparalysis could offer new epigenetic-based strategies to predict short- and long-term pathological events related to this life-threatening state. This review describes the most relevant epigenetic mechanisms underlying alterations in the innate and adaptive immune responses described in sepsis and septic shock, and their consequences for immunosuppression states, providing several candidates to become epigenetic biomarkers that could improve sepsis management and help predict immunosuppression in postseptic patients.

https://doi.org/10.2217/epi-2019-0329